| A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the … SS Lim, T Vos, AD Flaxman, G Danaei, K Shibuya, H Adair-Rohani, ... The lancet 380 (9859), 2224-2260, 2012 | 15404 | 2012 |
| Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis UA Liberman, SR Weiss, J Bröll, HW Minne, H Quan, NH Bell, ... New England Journal of Medicine 333 (22), 1437-1444, 1995 | 2993 | 1995 |
| Ten years' experience with alendronate for osteoporosis in postmenopausal women HG Bone, D Hosking, JP Devogelaer, JR Tucci, RD Emkey, RP Tonino, ... New England Journal of Medicine 350 (12), 1189-1199, 2004 | 1897 | 2004 |
| Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis KG Saag, R Emkey, TJ Schnitzer, JP Brown, F Hawkins, S Goemaere, ... New England Journal of Medicine 339 (5), 292-299, 1998 | 1588 | 1998 |
| Two‐year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double‐blind, placebo‐controlled extension trial JD Adachi, KG Saag, PD Delmas, UA Liberman, RD Emkey, E Seeman, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2001 | 718 | 2001 |
| Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women RP Tonino, PJ Meunier, R Emkey, JA Rodriguez-Portales, CJ Menkes, ... The Journal of Clinical Endocrinology & Metabolism 85 (9), 3109-3115, 2000 | 502 | 2000 |
| Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study B Langdahl, N Binkley, H Bone, N Gilchrist, H Resch, ... Journal of Bone and Mineral Research 27 (11), 2251-2258, 2012 | 191 | 2012 |
| A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the … S Stephen, T Vos, AD Flaxman, G Danaei, K Shibuya, H Adair-Rohani, ... London: J. Onwhyn London: Lancet Publishing Group, 2012 | 187 | 2012 |
| Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal P Ravn, SR Weiss, JA Rodriguez-Portales, MR McClung, RD Wasnich, ... The Journal of Clinical Endocrinology & Metabolism 85 (4), 1492-1497, 2000 | 152 | 2000 |
| Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study MR McClung, ML O'Donoghue, SE Papapoulos, H Bone, B Langdahl, ... The lancet Diabetes & endocrinology 7 (12), 899-911, 2019 | 140 | 2019 |
| Intracellular calcium and blood pressure: comparison between primary hyperparathyroidism and essential hypertension C Fardella, JA Rodriguez-Portales Journal of endocrinological investigation 18 (11), 827-832, 1995 | 55 | 1995 |
| The Alendronate Phase III Osteoporosis Treatment Study Group: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis UA Liberman, SR Weiss, J Broll, HW Minne, H Quan, NH Bell, ... N Engl J Med 333 (22), 1437-1443, 1995 | 53 | 1995 |
| Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study R Rizzoli, CL Benhamou, J Halse, PD Miller, IR Reid, ... Osteoporosis international 27, 2099-2107, 2016 | 48 | 2016 |
| A prepubertal surge of thyrotropin precedes an increase in thyroxine and 3, 5, 3′-triiodothyronine in normal children P MICHAUD, A FORADORI, JA RODRÍGUEZ-PORTALES, E ARTEAGA, ... The Journal of Clinical Endocrinology & Metabolism 72 (5), 976-981, 1991 | 44 | 1991 |
| Anti thyroglobulin antibodies in the follow up of patients with differentiated thyroid cancer: residual or relapsing disease markers? I Quevedo, C Campino, RP JA, E Arteaga, JM López, C Campusano, ... Revista médica de Chile 130 (2), 167-172, 2002 | 21 | 2002 |
| Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis: Results from the phase III long-term odanacatib fracture trial MR McClung, B Langdahl, S Papapoulos, KG Saag, S Adami, HG Bone, ... Osteoporosis International 25 (5), 2014 | 20 | 2014 |
| Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure JA Rodriguez-Portales, C Fardella Journal of Endocrinological Investigation 17 (5), 307-311, 1994 | 20 | 1994 |
| Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial A Denker, N Binkley, H Bone, N Gikhrist, B Langdahl, H Resch, ... MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY 18 (12), 1344-1344, 2011 | 9 | 2011 |
| Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III Long-Term Odanacatib Fracture Trial (LOFT) S Papapoulos, M McClung, B Langdahl, K Saag, S Adami, H Bone, ... Journal of Bone and Mineral Research 29, S51-S51, 2014 | 8 | 2014 |
| Prevención de osteoporosis PJA Rodríguez Revista Médica Clínica Las Condes 21 (5), 765-770, 2010 | 8 | 2010 |
